z-logo
open-access-imgOpen Access
Meta-Analysis of the Effect of Traditional Chinese Medicine Compounds Combined with Standard Western Medicine for the Treatment of Diabetes Mellitus Complicated by Coronary Heart Disease
Author(s) -
Mengqi Yang,
Min Cheng,
Min Wang,
Zhishu Tang,
Zhongxing Song,
Chunli Cui,
Yanru Liu,
Zhen Zhang
Publication year - 2021
Publication title -
evidence-based complementary and alternative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.552
H-Index - 90
eISSN - 1741-4288
pISSN - 1741-427X
DOI - 10.1155/2021/5515142
Subject(s) - medicine , diabetes mellitus , coronary heart disease , western medicine , traditional chinese medicine , traditional medicine , cardiology , alternative medicine , endocrinology , pathology
This study aimed to systematically evaluate the clinical efficacy and safety of traditional Chinese medicine (TCM) compounds combined with standard treatments for diabetes mellitus (DM) complicated by coronary heart disease (CHD). We performed a systematic and comprehensive search of the China Knowledge Network, WanFang, WeiPu, PubMed, and Web of Science, including Chinese and English articles, for randomized controlled trials (RCTs) assessing the use of Chinese herbal compounds for the treatment of DM complicated by CHD published before June 1, 2020. The literature was screened according to standard criteria. Risk assessment, based on the Jadad scale, was performed using the Review Manager5.3 software for meta-analysis. In total, 23 articles were selected, including 2405 cases. The meta-analysis showed that the combination of standard treatments with TCM compounds significantly improved the overall treatment efficacy for DM complicated by CHD (OR(odds ratio) = 4.39; 95% confidence interval (95% CI), 3.30–5.84; P < 0.0001), fasting blood glucose level (mean difference (MD) = −1.04; 95% CI, −1.96 to −0.13; P =0.03), total cholesterol level (MD = −1.16; 95% CI, −1.48 to −0.83; P < 0.0001), triglyceride (MD = −0.46; 95% CI, −0.62 to −0.29; P < 0.0001), low-density lipoprotein level (MD = −0.57; 95% CI, −0.87 to −0.27; P =0.0002), high-density lipoprotein level (MD = 0.19; 95% CI, 0.12 to 0.26; P =0.02), and electrocardiogram (OR = 4.20; 95% CI, 3.15 to 8.18; P < 0.0001). In contrast, there was no improvement of 2-hour postprandial glucose level (MD = −1.03; 95% CI, −2.14 to 0.08; P =0.07), or adverse reactions (OR = 0.53; 95% CI, 0.19 to 5.50; P =0.21). We concluded that the combined therapy has some benefits in treating DM complicated by CHD. However, these results should be confirmed by further referenced evidence, high risk assessment, and lower publication bias.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom